Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 30, 2020

PPD expands digital clinical trial solutions amid Covid-19 pandemic

Global contract research organisation PPD has extended its digital clinical trial capabilities to support biopharmaceutical firms’ research continuity initiatives in response to the Covid-19 pandemic.

Global contract research organisation PPD has extended its digital clinical trial capabilities to support biopharmaceutical firms’ research continuity initiatives in response to the Covid-19 pandemic.

The coronavirus outbreak is posing many challenges in the designing and conducting of clinical trials, majorly the inability of patients to visit research sites due to government-mandated lockdowns.

As part of the company’s digital strategy, PPD is collaborating with customers, regulatory authorities and business partners in order to deploy digital and virtual solutions.

PPD is investing in new clinical study models designed to improve the patient experience by reducing the number of in-person visits in favour of remote and digitally enabled participation of the study.

PPD digital services senior vice-president Niklas Morton said: “The pandemic’s impact is driving a new consensus that the need is now for expanded use of digitally enabled trials.

“Our flexible customer solutions across the digital spectrum are designed to increase trial-participation access for patients and enhance their experience, resulting in time-efficiency and data-quality improvements for our customers.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“In today’s challenging environment, our digital solutions can contribute to minimising trial disruptions and helping our customers keep their drug development programmes on track.”

In the wake of the Covid-19 impact on ongoing studies, PPD has partnered with Medable and Science 37 for virtual trials and is deploying new mobile applications that enable patients to connect visually with their clinical study sites, as well as allow investigators to complete safety assessments more efficiently.

Last month, ZyVersa Therapeutics engaged PPD to manage its upcoming Phase IIa focal segmental glomerulosclerosis (FSGS) study. FSGS is a leading cause of kidney failure in adults.

In December last year, PPD added significant neuroscience and ethno-bridging expertise, expanding its early development research services for its clinical research units (CRUs).

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU